- Home
- EBS vs RM Comparison
EBS vs RM Comparison
Compare EBS & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBS | RM |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.9M | 390.4M |
| IPO Year | 2006 | 2011 |
Fundamental Metrics
Financial Performance| Metric | EBS | RM |
|---|---|---|
| Price | $8.10 | $33.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 614.2K | 43.8K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | ★ 125.83 | 7.49 |
| EPS | 0.07 | ★ 1.18 |
| Revenue | ★ $742,900,000.00 | $645,598,000.00 |
| Revenue This Year | $1.29 | $12.94 |
| Revenue Next Year | N/A | $8.97 |
| P/E Ratio | $116.79 | ★ $29.77 |
| Revenue Growth | N/A | ★ 9.70 |
| 52 Week Low | $5.62 | $26.06 |
| 52 Week High | $14.06 | $46.00 |
Technical Indicators
Market Signals| Indicator | EBS | RM |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 42.37 |
| Support Level | $7.73 | $33.47 |
| Resistance Level | $8.95 | $35.43 |
| Average True Range (ATR) | 0.55 | 1.59 |
| MACD | -0.07 | -0.27 |
| Stochastic Oscillator | 27.17 | 8.65 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.